Wuwei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wuwei Yang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Baorang Zhu
Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
3 shared publicationsJing Li
Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China
3 shared publicationsLiyan Diao
Department of Tumor Minimally Invasive Treatment, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China
2 shared publicationsYing Liu
Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
2 shared publications- Bao-Rang Zhu
Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China
1 shared publication Dai-Lian Wang
Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9399-9413
Feasibility and Tolerability of Arterial Infusion Chemotherapy and Embolization for Recurrent/Metastatic Soft Tissue Sarcoma: A Retrospective Exploratory Study
Objective: This study aimed to evaluate the feasibility and tolerability of arterial infusion chemotherapy embolization (AICE) in treating recurrent/metastatic soft tissue sarcoma (STS) and to explore relevant prognostic factors to tailor future individualized treatment. Methods: A total of 113 patients with recurrent/metastatic STS treated with AICE at the Fifth Medical Center of the PLA General Hospital were included in this retrospective study. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier survival curves were adopted and univariate and multivariate analyses were conducted using the Cox proportional hazards model to evaluate prognostic factors. Treatment-related adverse events (TRAEs) were graded according to the Society of Interventional Radiology (SIR) standards. Results: Among the 113 patients, the median OS was 19.0 months (95% CI: 12.8– 25.3) with 2-year OS rates of 45.1%. The median PFS was 11.0 months (95% CI: 8.6– 13.4) with 2-year PFS rates of 25.7%. Objective response rate (ORR) was 37.2% (95% CI: 28.3%– 46.8%) and disease control rate (DCR) was 76.1% (95% CI: 67.1%– 83.6%). Univariate analysis revealed that tumor size, presence of distant metastasis, number of postoperative treatment regimens, pathological differentiation and neutrophil-to-lymphocyte ratio (NLR) were significantly associated with OS and PFS (P< 0.05). Multivariate Cox analysis confirmed that tumor size, distant metastasis, number of postoperative treatment regimens, pathological differentiation and short-term efficacy were independent prognostic factors for OS (P< 0.05). The most common TRAEs were pain (23.0%), transient bone marrow suppression (15.0%) and postoperative fever (6.2%). No severe or fatal adverse reactions and treatment-related mortalities were observed, demonstrating superior tolerability. Conclusion: AICE might be a feasible and well-tolerated treatment for recurrent/metastatic STS, effectively controlling disease progression and improving survival outcomes in this retrospective cohort. Further multicenter, large-scale prospective studies were needed to validate these findings and explore the combination of AICE with immunotherapy or targeted therapy to optimize treatment strategy for STS.
- 1 October 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9399-9413
Open AccessFeasibility and Tolerability of Arterial Infusion Chemotherapy and Embolization for Recurrent/Metastatic Soft Tissue Sarcoma: A Retrospective Exploratory Study
Objective: This study aimed to evaluate the feasibility and tolerability of arterial infusion chemotherapy embolization (AICE) in treating recurrent/metastatic soft tissue sarcoma (STS) and to explore relevant prognostic factors to tailor future individualized treatment. Methods: A total of 113 patients with recurrent/metastatic STS treated with AICE at the Fifth Medical Center of the PLA General Hospital were included in this retrospective study. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier survival curves were adopted and univariate and multivariate analyses were conducted using the Cox proportional hazards model to evaluate prognostic factors. Treatment-related adverse events (TRAEs) were graded according to the Society of Interventional Radiology (SIR) standards. Results: Among the 113 patients, the median OS was 19.0 months (95% CI: 12.8– 25.3) with 2-year OS rates of 45.1%. The median PFS was 11.0 months (95% CI: 8.6– 13.4) with 2-year PFS rates of 25.7%. Objective response rate (ORR) was 37.2% (95% CI: 28.3%– 46.8%) and disease control rate (DCR) was 76.1% (95% CI: 67.1%– 83.6%). Univariate analysis revealed that tumor size, presence of distant metastasis, number of postoperative treatment regimens, pathological differentiation and neutrophil-to-lymphocyte ratio (NLR) were significantly associated with OS and PFS (P< 0.05). Multivariate Cox analysis confirmed that tumor size, distant metastasis, number of postoperative treatment regimens, pathological differentiation and short-term efficacy were independent prognostic factors for OS (P< 0.05). The most common TRAEs were pain (23.0%), transient bone marrow suppression (15.0%) and postoperative fever (6.2%). No severe or fatal adverse reactions and treatment-related mortalities were observed, demonstrating superior tolerability. Conclusion: AICE might be a feasible and well-tolerated treatment for recurrent/metastatic STS, effectively controlling disease progression and improving survival outcomes in this retrospective cohort. Further multicenter, large-scale prospective studies were needed to validate these findings and explore the combination of AICE with immunotherapy or targeted therapy to optimize treatment strategy for STS.
- Open Access
- 22 July 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (3)
A stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment: A case report
Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with ERBB2 amplification or ERBB2 overexpression. Whether these patients will benefit from ERBB2 inhibitors remains unclear. Herein, we report a patient with metastatic HGSOC carrying ERBB2 amplification and ERBB2 overexpression. Following progression to platinum-based chemotherapy and subsequent antiangiogenic therapies, the patient benefited from late-line pyrotinib treatment, achieving stable disease with a progression-free survival of 9.5 months. Our study provides preliminary clinical evidence supporting pyrotinib as a feasible treatment option for metastatic HGSOC patients with ERBB2 amplification and/or ERBB2 overexpression. Prospective trials of pyrotinib should be conducted in appropriately selected OC populations.
- 22 July 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (3)
Open AccessA stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment: A case report
Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with ERBB2 amplification or ERBB2 overexpression. Whether these patients will benefit from ERBB2 inhibitors remains unclear. Herein, we report a patient with metastatic HGSOC carrying ERBB2 amplification and ERBB2 overexpression. Following progression to platinum-based chemotherapy and subsequent antiangiogenic therapies, the patient benefited from late-line pyrotinib treatment, achieving stable disease with a progression-free survival of 9.5 months. Our study provides preliminary clinical evidence supporting pyrotinib as a feasible treatment option for metastatic HGSOC patients with ERBB2 amplification and/or ERBB2 overexpression. Prospective trials of pyrotinib should be conducted in appropriately selected OC populations.
- Open Access
- 17 December 2019
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (1) , 15-18
Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report
Cervical carcinosarcoma is an extremely rare type of neoplasm that lacks standard of care. Preclinical and clinical evidence has suggested that cryoablation in combination with immunotherapy may result in a synergistic effect, generating a more robust immune response to distant lesions. A few clinical trials have evaluated the efficacy of such combination treatment in a variety of solid tumors, but with conflicting results. This report describes the first clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden (TMB)-high metastatic cervical carcinosarcoma that was negative for programmed cell death protein 1 expression, microsatellite instability stable, and had mutations in DNA polymerase epsilon (POLE). She had achieved complete response (CR) after 3 months of pembrolizumab treatment and had maintained CR as of the time of submission of this manuscript, with a progression-free survival of 11 months and counting. The case exhibited an exceptional response to cryoablation followed by pembrolizumab, potentially attributed to mutations in POLE, which lead to an extremely high TMB. This report paves the avenue for establishing treatment regimens for patients with TMB-high cervical carcinosarcoma. Key Points: Owing to its rarity, cervical carcinosarcoma has not been well characterized, and currently, there is no standard of care for this disease. This report describes the first case of clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden-high metastatic cervical carcinosarcoma. The case exhibited an exceptional response (maintained CR as of the time of submission of this article: 11 months) to cryoablation followed by pembrolizumab. This is the first POLE-mutated cervical carcinosarcoma case.
- 17 December 2019
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (1) , 15-18
Open AccessExceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report
Cervical carcinosarcoma is an extremely rare type of neoplasm that lacks standard of care. Preclinical and clinical evidence has suggested that cryoablation in combination with immunotherapy may result in a synergistic effect, generating a more robust immune response to distant lesions. A few clinical trials have evaluated the efficacy of such combination treatment in a variety of solid tumors, but with conflicting results. This report describes the first clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden (TMB)-high metastatic cervical carcinosarcoma that was negative for programmed cell death protein 1 expression, microsatellite instability stable, and had mutations in DNA polymerase epsilon (POLE). She had achieved complete response (CR) after 3 months of pembrolizumab treatment and had maintained CR as of the time of submission of this manuscript, with a progression-free survival of 11 months and counting. The case exhibited an exceptional response to cryoablation followed by pembrolizumab, potentially attributed to mutations in POLE, which lead to an extremely high TMB. This report paves the avenue for establishing treatment regimens for patients with TMB-high cervical carcinosarcoma. Key Points: Owing to its rarity, cervical carcinosarcoma has not been well characterized, and currently, there is no standard of care for this disease. This report describes the first case of clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden-high metastatic cervical carcinosarcoma. The case exhibited an exceptional response (maintained CR as of the time of submission of this article: 11 months) to cryoablation followed by pembrolizumab. This is the first POLE-mutated cervical carcinosarcoma case.
- 24 January 2019
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 27 (4) , 423-433
Stimuli-responsive nanoscale drug delivery systems for cancer therapy
Currently, with the rapid development of nanotechnology, novel drug delivery systems have made rapid progress, in which nanocarriers play an important role in the tumor treatment. In view of the conventional chemotherapeutic drugs with many restrictions such as non-specific systemic toxicity, short half-life and low concentration in the tumor sites, stimuli-responsive drug delivery systems can deliver anti-tumor drugs targeting to the specific sites of tumors. Owing to precise stimuli response, stimuli-responsive drug delivery systems can control drug release, so as to improve the curative effects, reduce the damage of normal tissues and organs, and decrease the side effects of traditional anti-cancer drugs. At present, according to the physicochemical properties and structures of nanomaterials, they can be divided into three categories: 1) endogenous stimuli-responsive materials, including pH, enzyme and redox responsive materials; 2) exogenous stimuli-responsive materials, such as temperature, light, ultrasound and magnetic field responsive materials; 3) multi-stimuli responsive materials. This review mainly focuses on the researches and developments of these novel stimuli-responsive drug delivery systems based on above-mentioned nanomaterials and their clinical applications.
- 24 January 2019
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 27 (4) , 423-433
Stimuli-responsive nanoscale drug delivery systems for cancer therapy
Currently, with the rapid development of nanotechnology, novel drug delivery systems have made rapid progress, in which nanocarriers play an important role in the tumor treatment. In view of the conventional chemotherapeutic drugs with many restrictions such as non-specific systemic toxicity, short half-life and low concentration in the tumor sites, stimuli-responsive drug delivery systems can deliver anti-tumor drugs targeting to the specific sites of tumors. Owing to precise stimuli response, stimuli-responsive drug delivery systems can control drug release, so as to improve the curative effects, reduce the damage of normal tissues and organs, and decrease the side effects of traditional anti-cancer drugs. At present, according to the physicochemical properties and structures of nanomaterials, they can be divided into three categories: 1) endogenous stimuli-responsive materials, including pH, enzyme and redox responsive materials; 2) exogenous stimuli-responsive materials, such as temperature, light, ultrasound and magnetic field responsive materials; 3) multi-stimuli responsive materials. This review mainly focuses on the researches and developments of these novel stimuli-responsive drug delivery systems based on above-mentioned nanomaterials and their clinical applications.
- 24 January 2018
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 19 (3) , 198-204
Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study
Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of apatinib was 372.9 ± 68.4 mg/day. In the study cohort, one patient was treated as adjunctive therapy and 6 patients stopped treatment before radiographic response assessment. Thus, 24 patients were eligible for tumor response evaluation. The objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. The progression free survival was 4.25 (95% confidence interval [CI], 2.22–5.11) months, whereas the overall survival was 9.43 (95% CI, 6.64–18.72) months. Compared with other histological subtypes, leiomyosarcoma did not show significant survival benefits. Most of the adverse events (AEs) were at grade 1 or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials.
- 24 January 2018
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 19 (3) , 198-204
Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study
Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of apatinib was 372.9 ± 68.4 mg/day. In the study cohort, one patient was treated as adjunctive therapy and 6 patients stopped treatment before radiographic response assessment. Thus, 24 patients were eligible for tumor response evaluation. The objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. The progression free survival was 4.25 (95% confidence interval [CI], 2.22–5.11) months, whereas the overall survival was 9.43 (95% CI, 6.64–18.72) months. Compared with other histological subtypes, leiomyosarcoma did not show significant survival benefits. Most of the adverse events (AEs) were at grade 1 or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials.